Keyphrases
Chemotherapy
66%
Chemotherapy-induced
40%
Systematic Meta-analysis
39%
Doxorubicin
38%
Meta-analysis
35%
Vascular Toxicity
29%
Cancer Patients
29%
Fertility Preservation
28%
Malignancy
26%
Breast Cancer Patients
24%
Calpain
24%
Testicular Toxicity
21%
Cisplatin
21%
COVID-19
20%
Ovarian Toxicity
20%
Cancer Treatment
19%
Israel
19%
Young Patients
19%
Ovarian Reserve
18%
Tumor
18%
Anti-Mllerian Hormone
18%
Hazard Ratio
17%
Patients with Cancer
17%
Gastrointestinal Cancer
16%
Gastrointestinal Tract Cancer
16%
Esophageal Cancer
16%
Phase II Trial
16%
Early Onset
16%
High Risk
16%
Overall Survival
16%
Confidence Interval
15%
Chemotherapy-induced Ovarian Failure
14%
Colorectal Cancer
14%
Breast Cancer
14%
Breast Cancer Susceptibility Gene 1 (BRCA1)
13%
Recurrence Score
13%
In Cancer
13%
Placebo
12%
Oncotype DX
12%
Oxaliplatin
12%
Gonadotropin-releasing Hormone
12%
BRCA1, BRCA2
12%
Cancer-related
12%
Neoadjuvant Therapy
12%
Meta-analysis of Randomized Controlled Trials
11%
Cyclophosphamide
11%
Pediatric
11%
Trastuzumab
11%
Risk Ratio
11%
Apoptosis
11%
Medicine and Dentistry
Malignant Neoplasm
83%
Breast Cancer
50%
Cancer
34%
Neoplasm
34%
Colorectal Carcinoma
33%
Fertility Preservation
28%
Oocyte
26%
Gastrointestinal Cancer
24%
Recurrent Disease
22%
Doxorubicin
22%
COVID-19
21%
Ovarian Reserve
21%
Diseases
19%
Cancer Treatment
19%
Programmed Cell Death
17%
Systematic Review
16%
Meta-Analysis
16%
Neoadjuvant Therapy
16%
Abdominal Cancer
16%
Hormone Determination
16%
Oncology
15%
Muellerian Inhibiting Factor
15%
Ovary Insufficiency
14%
Vascularity
14%
Metastatic Carcinoma
14%
Overall Survival
14%
Placebo
14%
Immunotherapy
13%
Diarrhea
13%
Blood Flow
13%
Radiation Therapy
12%
Esophageal Cancer
12%
Oxaliplatin
12%
Pediatrics
12%
Oncotype DX
11%
Adverse Event
11%
Gold Nanoparticle
11%
Aromatase Inhibitor
11%
Prostate Cancer
11%
Retrospective Study
11%
Gastrointestinal Tract
11%
Rotavirus
11%
Pembrolizumab
11%
Heat Shock Transcription Factor 1
11%
Colon Carcinoma
11%
Adenocarcinoma
11%
Follitropin
11%
Biological Marker
10%
Squamous Cell Carcinoma
9%
Esophageal Adenocarcinoma
9%
Pharmacology, Toxicology and Pharmaceutical Science
Chemotherapy
100%
Malignant Neoplasm
77%
Breast Cancer
46%
Doxorubicin
29%
Colorectal Carcinoma
27%
Diseases
24%
Calpain
22%
Abdominal Cancer
22%
Cisplatin
20%
Neoplasm
18%
Overall Survival
18%
Randomized Controlled Trial
16%
Diarrhea
16%
Recurrent Disease
15%
Ovary Insufficiency
15%
Digestive System Cancer
13%
Oxaliplatin
12%
Chemoradiation Therapy
11%
Follitropin
11%
Cyclophosphamide
11%
Dyspnea
11%
Docetaxel
11%
Calpastatin
11%
Rotavirus
11%
Immunotherapy
11%
Colon Carcinoma
11%
Adverse Event
10%
Epidermal Growth Factor Receptor
10%
Placebo
9%
Trastuzumab
8%
Gonadorelin Antagonist
8%
Disease Free Survival
8%
Rotavirus Vaccine
8%
Blood Vessel Injury
7%
Gonadorelin Agonist
7%
Adenocarcinoma
7%
Survival Rate
7%
Biological Marker
7%
Busulfan
6%
Cetuximab
6%
Tumor Growth
6%
Low Molecular Weight Heparin
6%
Head and Neck Cancer
6%
Squamous Cell Carcinoma
6%
Pancreas Cancer
6%
Diethylstilbestrol
6%
Taxane
6%
Fluorouracil
6%
microRNA
5%
Bisphosphonic Acid Derivative
5%